Journal Article

DKFZ-2019-02447

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The Phase I/II ACCEPT Trial: Concurrent Cetuximab and Intensity-Modulated Radiotherapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck: Cetuximab and IMRT/Carbon Ions for ACC.

Adeberg, S. (First author)DKFZ* ; Akbaba, S. ; Lang, K. ; Held, T. ; Verma, V. ; Nikoghosyan, A. ; Bernhardt, D. ; Münter, M. ; Freier, K. ; Plinkert, P. ; Hauswald, H. ; Herfarth, K.DKFZ* ; Rieken, S.DKFZ* ; Debus, J.DKFZ* ; Jensen, A. D.

2020
Elsevier Science Amsterdam [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.ijrobp.2019.09.036

Abstract: The Phase I/II ACCEPT Trial: Concurrent Cetuximab and Intensity-Modulated Radiotherapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck: Cetuximab and IMRT/Carbon Ions for ACC.

Note: 2020 Jan 1;106(1):167-173#EA:E050#

---

Contributing Institute(s):

1. E050 KKE Strahlentherapie (E050)

Research Program(s):

1. 315 - Imaging and radiooncology (POF3-315) (POF3-315)

Appears in the scientific report 2020

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---